Top Markets
#1 QuantixAI QuantixAI +102.23%
#2 龙虾 (Lobster) 龙虾 (Lobster) +33.16%
#3 Pons Pons +30.55%
#4 Rain Rain +28.95%
#5 MetaDAO MetaDAO +25.95%
#6 DOG•GO•TO•THE•MOON (Runes) DOG•GO•TO•THE•MOON (Runes) +25.81%
#7 Bedrock Bedrock +20.38%
#8 Ontology Gas Ontology Gas +18.04%
#9 Prom Prom +17.73%
#10 peaq peaq +16.82%
Coin of the day
QuantixAI QuantixAI
Pengaturan
Bahasa
BAHASA INDONESIA
Mata uang
USD
Tema
Grifols, S.A. Grifols, S.A.

Grifols, S.A.

GRF
Peringkat dalam Saham #2542
Grifols, S.A., a Spanish company established in 1940 and headquartered in... Grifols, S.A., a Spanish company established in 1940 and headquartered in Barcelona, specializes in the comprehensive process of acquiring, manufacturing, preparing, and distributing therapeutic products, with a primary focus on those derived from plasma. The company operates through several key divisions: Bioscience, Hospital, Diagnostic, and Bio Supplies, among others. The Bioscience division is dedicated to the research, development, production, and commercialization of plasma-derived medicines and other cutting-edge solutions. These are designed to treat individuals suffering from chronic, rare, widespread, and life-threatening medical conditions, with its product portfolio including immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division supplies a range of non-biological pharmaceutical products, clinical nutrition items, intravenous (IV) therapy solutions, and various medical devices and supplies. Grifols' Diagnostic division develops and markets advanced diagnostic tools that support healthcare professionals across the entire patient care continuum, from prevention and screening to accurate diagnosis, prognosis, and ongoing disease and treatment monitoring. Finally, the Bio Supplies division provides essential biological materials for life-science research, clinical trials, and the manufacturing of both pharmaceutical and diagnostic goods. Collectively, Grifols' offerings enable healthcare providers to effectively diagnose and treat a broad spectrum of medical conditions, such as hemophilia, various immune deficiencies, and infectious diseases. Its diverse client base includes public and private sector organizations, wholesalers, distributors, group purchasing organizations (GPOs), blood banks, hospitals, care institutions, and national health systems. Grifols also maintains a technology collaboration agreement with Mondragon.
Harga Saham
$11.91
Kapitalisasi Pasar
$8.11B
Perubahan (1 hari)
1.67%
Perubahan (1 tahun)
-16.23%
Negara
ES
Perdagangan Grifols, S.A. (GRF)

Kategori

Healthcare
Pendapatan untuk Grifols, S.A. (GRF)
Pendapatan pada Aug 2026 TTM: 0
Menurut laporan keuangan terbaru dari Grifols, S.A., pendapatan saat ini (TTM) adalah 0. Pada tahun 2026, perusahaan menghasilkan pendapatan sebesar 0 sama dengan pendapatan pada tahun 2026 yang sebesar 0. Pendapatan adalah jumlah total yang dihasilkan dari penjualan barang atau jasa. Tidak seperti laba, tidak ada pengeluaran yang dikurangkan.
Riwayat pendapatan Grifols, S.A. dari 2026 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Pendapatan untuk perusahaan serupa atau pesaing
Perusahaan Pendapatan Perbedaan Pendapatan Negara
Eli Lilly and Company Eli Lilly and Company
Eli Lilly and Company
LLY.US
 $79.67B -
US
Johnson & Johnson Johnson & Johnson
Johnson & Johnson
JNJ.US
 $97.93B -
US
AbbVie Inc. AbbVie Inc.
AbbVie Inc.
ABBV.US
 $64.39B -
US
Roche Holding AG Roche Holding AG
Roche Holding AG
RO.SW
 $77.52B -
CH
Merck & Co., Inc. Merck & Co., Inc.
Merck & Co., Inc.
MRK.US
 $66.40B -
US